U.S. flag

An official website of the United States government

NM_001371333.1(DIABLO):c.50+5C>T AND not provided

Germline classification:
Conflicting interpretations of pathogenicity (2 submissions)
Last evaluated:
Feb 10, 2022
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000728075.10

Allele description [Variation Report for NM_001371333.1(DIABLO):c.50+5C>T]

NM_001371333.1(DIABLO):c.50+5C>T

Genes:
LOC130009040:ATAC-STARR-seq lymphoblastoid active region 7211 [Gene]
DIABLO:diablo IAP-binding mitochondrial protein [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
12q24.31
Genomic location:
Preferred name:
NM_001371333.1(DIABLO):c.50+5C>T
HGVS:
  • NC_000012.12:g.122225960G>A
  • NG_029459.1:g.6562C>T
  • NM_001278302.1:c.-81+5C>T
  • NM_001278303.1:c.-37+5C>T
  • NM_001278342.1:c.50+5C>T
  • NM_001371333.1:c.50+5C>TMANE SELECT
  • NM_019887.6:c.50+5C>T
  • NM_138930.3:c.-81+5C>T
  • NC_000012.11:g.122710507G>A
Links:
dbSNP: rs372776075
NCBI 1000 Genomes Browser:
rs372776075
Molecular consequence:
  • NM_001278302.1:c.-81+5C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001278303.1:c.-37+5C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001278342.1:c.50+5C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001371333.1:c.50+5C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_019887.6:c.50+5C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_138930.3:c.-81+5C>T - intron variant - [Sequence Ontology: SO:0001627]
Observations:
1

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000855604Eurofins Ntd Llc (ga)
criteria provided, single submitter

(EGL Classification Definitions 2015)
Uncertain significance
(Jul 24, 2017)
germlineclinical testing

Citation Link,

SCV002398175Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely benign
(Feb 10, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Eurofins Ntd Llc (ga), SCV000855604.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided1not providednot providednot provided

From Invitae, SCV002398175.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 14, 2024